If you listen to analysts' calls, Incivek will be obsolete very soon. However, some of data for hcv genotype 2 suggest that it is not inferior to the best nucleotide-analog and superior to other PIs for genotype 1. Here is an example. The following results were taken out of Clinical-Care-Options slides which came from a publication dated last year. The link to the slides is:
You may have to register to enter the CCO site and download the slides.
For the genotype 2, a 15 day course of Incivek/pegI/RBV followed by 22-24 weeks of pegI/RBV achieved an SVR rate of 100%. It was a small trial, but if Incivek had been given for 12 weeks instead of just 2 weeks as done for this trial, a total treatment duration of just 12 weeks would be enough for a good SVR rate.
<* If you listen to analysts' calls, Incivek will be obsolete very soon.*>
Which analyst say so since I want to call him/her crazy, stupid and out of brain. Just look at Victrelis with all its problems, FDA warning and lack of effective(takes 24 to 48 weeks compare to 12 weeks of Incivek) but still gets 20% of market.
Bottom line is about pricing. There won't be any generic for at least 15 years to slash prices and Incivek will be sold in US and all over 15 years.